BridgeBio Pharma, Inc , a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases owned by Zydus Lifesciences Ltd. announced the European Commission (EC) has granted marketing authorization for NULIBRY (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.
- Read more about BridgeBio Pharma and Zydus US arm gets EU approval for NULIBRY
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/bridgebio-pharma-and-zydus-us-arm-gets-eu-approval-for-nulibry
No comments:
Post a Comment